Literature DB >> 29776936

Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis.

Meijun Si1, Huiqun Li1, Yanru Chen1, Hui Peng1.   

Abstract

Ethambutol (EMB) and isoniazid (INH) are the first-line antituberculosis (anti-TB) drugs. However, their neurotoxicity could cause adverse effect and the patients with end-stage renal disease are especially vulnerable due to the reduction in renal drug clearance. Here, we report a 36-year-old man receiving peritoneal dialysis developed progressive paralysis in lower extremities, vision loss and hoarseness 4 months after anti-TB treatment with INH, EMB and rifapentine because of concomitant pulmonary tuberculosis. A diagnosis of EMB/INH-induced peripheral neuropathy, retrobulbar neuritis and laryngoparalysis was made. The patient's neuropathy gradually improved 2 years after discontinuation of EMB/INH. Since EMB and INH may cause simultaneously severe and complex multineuropathy in dialysis patients, their adverse effects should be closely supervised in dialysis patients. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  dialysis; peripheral nerve disease; tuberculosis; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2018        PMID: 29776936      PMCID: PMC5965810          DOI: 10.1136/bcr-2017-223187

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  35 in total

1.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

2.  Tuberculosis (NICE clinical guideline 33).

Authors:  Louise Turnbull; Christine Bell; Fran Child
Journal:  Arch Dis Child Educ Pract Ed       Date:  2016-12-14       Impact factor: 1.309

3.  The ocular toxicity of ethambutol and its relation to dose.

Authors:  J E Leibold
Journal:  Ann N Y Acad Sci       Date:  1966-04-20       Impact factor: 5.691

4.  [Pharmacokinetics of ethambutol in healthy individuals and in patients with terminal renal failure].

Authors:  T Dume; C Wagner; E Wetzels
Journal:  Dtsch Med Wochenschr       Date:  1971-09-03       Impact factor: 0.628

5.  Impact of chronic renal failure on anti-tuberculosis treatment outcomes.

Authors:  P Baghaei; M Marjani; P Tabarsi; A Moniri; F Rashidfarrokhi; F Ahmadi; A-A Nassiri; M-R Masjedi; A A Velayati; A Cattamanchi
Journal:  Int J Tuberc Lung Dis       Date:  2014-03       Impact factor: 2.373

Review 6.  Nervous system effects of antituberculosis therapy.

Authors:  Joseph S Kass; Wayne X Shandera
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

7.  Ethambutol Is Cleared by a Contemporary High-Flux Hemodialyzer, and Drug Monitoring Ensures Safety and Therapeutic Effect.

Authors:  Rusheng Chew; Sarah Jongbloed; Dev Jegatheesan; Helen Healy; Kim Ta; Jacobus Ungerer; Brett McWhinney; Peter Donovan; Marion L Woods
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

Review 8.  Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature.

Authors:  M S Siskind; D Thienemann; L Kirlin
Journal:  Nephron       Date:  1993       Impact factor: 2.847

9.  Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin.

Authors:  Curie Ahn; Kook-Hwan Oh; Kiwon Kim; Kyung Yi Lee; Jung Geon Lee; Myung Don Oh; Yonsu Kim; Jin Suk Han; Suhnggwon Kim; Jung Sang Lee; In-Jin Jang; Sang-Goo Shin
Journal:  Perit Dial Int       Date:  2003 Jul-Aug       Impact factor: 1.756

10.  Side-effects of antituberculosis drug treatment in patients with chronic renal failure.

Authors:  S J Quantrill; M A Woodhead; C E Bell; C C Hardy; A J Hutchison; R Gokal
Journal:  Eur Respir J       Date:  2002-08       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.